MedPath

Improving newborn survival in late preterm birth

Phase 3
Completed
Conditions
Health Condition 1: null- Prevention of neonatal deaths by administration of Antenatal Corticosteroids to women with a live fetus/es at risk of imminent preterm birth from 34 weeks 0 days to 35 weeks 6 days gestationHealth Condition 2: P220- Respiratory distress syndrome of newborn
Registration Number
CTRI/2017/05/008721
Lead Sponsor
World Health Organization
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
778
Inclusion Criteria

1 Birth planned or expected within 48 hours

2 Gestational age from 34 weeks 0 days to 36 weeks 0 days

3 Women with singleton or multiple pregnancies, where the fetus(es) is(are) alive

4 Women with no clinical signs of severe infection (as per clinical assessment)

5 Women willing and able to provide consent

Women with the following conditions are eligible. Any comorbid conditions will be managed according to local guidelines, and in line with WHO recommendations:

6 Women with a history of previous preterm birth

7 Women with hypertensive disorders

8 Women with a growth impaired fetus

9 Women with pre-gestational or gestational diabetes

10 Women with HIV/AIDs

Exclusion Criteria

1 Intrauterine fetal death

2 Major or lethal congenital fetal anomaly identified

3 Clinical suspicion or evidence of clinical chorioamnionitis, as per obstetric care physician assessment

4 Clinical suspicion or evidence of severe infection, as per obstetric care physician assessment

5 No prior ultrasound-based estimate of gestational age available and immediate ultrasound examination is not possible

6 Any concurrent or recent (within the past 2 weeks) systemic corticosteroid use during the current pregnancy (outside of trial)

7 Unwilling or unable to provide consent

Currently a participant in another clinical trial related to maternal and neonatal health

8 Any other clinical indication where the treating clinician considers corticosteroids to be contraindicated

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath